Persomics Chooses AstraZeneca BioHub in Waltham, Massachusetts for USA Headquarters

Share Article

Persomics USA Inc., a leading biotechnology company with innovative solutions that miniaturize, accelerate and increase the scale of functional genomics and phenotypic screening, has decided to establish its world-class laboratory and US headquarters in Waltham, MA.

Persomics USA Inc., a leading biotechnology company with innovative solutions that miniaturize, accelerate and increase the scale of functional genomics and phenotypic screening, has decided to establish its world-class laboratory and US headquarters in Waltham, MA. 
 
Persomics chose Waltham, MA, above other possible locations for its proximity to many biotech and life science companies in the Boston area, the high quality facilities at AstraZeneca’s Gatehouse Park BioHub, and for the valuable business support offered by the Massachusetts Life Sciences Center. 
 
“The fertile scientific and clinical environment of the Boston area will be a perfect location for Persomics, and I am very pleased with the response we have received from everyone we have interacted with thus far.”, says Neil Emans Ph.D. CEO of Persomics USA Inc. “As one of select group of companies we have been offered the opportunity to set up within the AstraZeneca “BioHub” Research Center at Gatehouse Drive in Waltham.  The facilities are of the absolute highest standards and will provide an invigorating collaborative research and business development environment.”
 
“Persomics is a great example of the kind of innovative companies that we are trying to attract to the BioHub as part of our ambition to create a more open research environment where our scientists can interact and push the boundaries of science”, says Karan Paruvangada, Director, Strategic Programs at AstraZeneca Waltham. 
 
About Persomics
Persomics provides ImagineArraysTM, a technology that miniaturizes, accelerates increases the scale of possible experiments. Researchers investigating the function of the human genome and disease are no longer limited by automation requirements or cost, but by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster. For more information, please visit persomics.com

Please send enquiries to:
Michael Sjaastad, Ph.D.
Chief Commercial Officer
mike(dot)sjaastad(at)persomics(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mike Sjaastad
Persomics
+1 (650) 678-9097
Email >
Visit website